有机阳离子转运体的基因多态性研究进展

摘要/Abstract

摘要： 人体的肝脏、肾脏和肠道上广泛分布有各种转运蛋白,其中有机阳离子转运体(OCTs)负责转运一些内、外源性的有机阳离子的转运。在此我们主要讨论的是OCTs 家族的成员OCT1 和OCT2 的基因多态性以及其功能意义。同时我们也就OCT 对于药物代谢动力学以及药效学的影响进行阐述,以及OCTs 在药物相互作用上的意义。

关键词: 有机阳离子转运体, 基因多态性, 药代动力学

Abstract: Various kinds of transporters exist in human organs, such as liver, kidney and intestine.The transport of cationic substrates which include endogenous metabolites, exotic substance, and drugs was mainly executed by different organic cation transporters (OCTs).In this article the genetic polymorphisms and their influences on OCTs funtions were mainly reviewed.Meanwhile, the recent findings of OCTs polymorphism influences on pharmacodynamics and pharmacokinetics value of several clinical widely used drugs were also included in this review.

Key words: organic cation transporter, genetic polymorphism, pharmacokinetics

中图分类号:

R969

韩林志, 周宏灏. 有机阳离子转运体的基因多态性研究进展[J]. 中国临床药理学与治疗学, 2009, 14(4): 460-464.

HAN Lin-zhi, ZHOU Hong-hao. DPHDevelopment of the genetic polymorphism study on organic cation transporters[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 460-464.

参考文献

[1] Zhang L, Dresser MJ, Gray AT, et al.Cloning and Functional expression of a human liver organic cation transporter[J].Molecuar Pharmacology, 1997, (51):913-921.
[2] Jonker JW, Schinkel AH.Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)[J].J Pharmacol Exp Ther, 2004, 308(1):2-9.
[3] Wang DS, Jonker JW, Kato Y, et al.Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin[J].J Pharmacol Exp Ther, 2002, 302 (2):510-515.
[4] Koepsell H, Endo H.The SLC22 drug transporter family [J].Pflugers Arch, 2004, 447(5):666-676.
[5] Bourdet DL, Pritchard JB, Thakker DR, et al.Differential substrate and inhibitory activities of ranitidine and famotidine toward hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)[J].JPET, 2005, 315(3):1288-1297.
[6] Choi MK, Song IS.Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences[J]. Drug Metab Pharmacokinet, 2008, 23(4):243-253.
[7] Kimura N, Masuda S, Tanahara Y, et al.Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepaticOCT1[J].Drug Metab Pharmacokinet, 2005, 20(5):379-386.
[8] Kerb R, Brinkmann U, Chatskaia N, et al.Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences[J].Pharmacogenetics, 2002, 12(8):591-595.
[9] LeabmanMK, Huang CC, Young JD, et al.Natural variation in human membrane transporter genes reveals evolutionary and functional constraints[J].PANS, 2003, 100 (10):5896-5901.
[10] Saito S, Iida A, Seki A, et al.Catalog of 238 variations among six human genes encoding solute carriers (hSLCs)in the Japanese population[J].J Hum Genet, 2002, 47 (11):576-584.
[11] Sakata T, Anzai N, Shin HJ, et al.Novel single nucleotide polymorphisms of organic cation transporter 1(SLC22A1)affecting transport functions[J].Biochem Biophys Res Commun, 2004, 313(3):789-793.
[12] Itoda M, Saito Y, Maekawa K, et al.Seven novel single nucleotide polymorphisms in the huanm SLC22A1 gene encoding organic cation transporter 1 (OCT1 )[J].Drug Metab Pharmacokin, 2004, 19(4):308-312.
[13] Kang HJ, Song IS, Shin HJ, et al.Identification and functional characterization of genetic variants of human organic cation transporters in a korean population[J].Drug Metab Dispos, 2007, 35(4):667-675.
[14] White DL, Saunders VA, Dang P, et al.OCT1 mediated influx is a key determinant of the intra cellular uptake of imatinib but not nilotinib (AMN107):reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib[J]. Blood, 2006, 108(2):697-704.
[15] Wang L, Giannoudis A, Lane S, et al.Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia[J].Clin Pharmacol Ther, 2008, 83(2):258-264.
[16] Shu Y, Sheardown SA, Brown C, et al.Effect of genetic variation in the organic cation transporter 1 (OCT1)on metformin action[J].J Clin Invest, 2007, 117(5):1422-1431.
[17] Takane H, Shikata E, Otsubo K, et al.Polymorphism in human organic cation transpriters and metformin action [J].Pharmacogenomics, 2008, 9(4):415-422.
[18] White D, Saunders V, Lyons AB, et al.In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML[J].Blood, 2005, 106(7):2520-2526.
[19] Burger H, Van TH, Boersma AW, et al.Imatinib mesylate (STI571)is a substrate for the breast cancer resistance protein (BCRP)ABCG2 drug pump[J].Blood, 2004, 104(9):2940-2942.
[20] Hamada A, Miy ano H, Watanabe H, et al.Interaction of imatinib mesilate with human P-glycoprotein[J].J Pharmacol Exp Ther, 2003, 307(2):824-828.
[21] Kang HJ, Song IS, Shin HJ, et al.Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population[J].Drug Metab Dispos, 2007, 35(4):667-675.
[22] Song I, Shin H, Shim E, et al.Genetic variants of the organic cation transporter 2 influence the disposition of metformin[J].Clin Pharmacol Ther, 2008, 84(5):559-562.
[23] Fujita T, Urban TJ, Leabman MK, et al.Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants[J].J Pharm Sci, 2006, 95(1):25-36.
[24] Kimura N, Masuda S, Tanihara Y, et al.Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1[J].Drug Metab Pharmacokinet,2005, 20(5):379-386.
[25] Kimura N, Okuda M, Inui K, et al.Metformin transport by renal basolateral organic cation transporter hOCT2[J].Pharm Res, 2005, 22(2):255-259.
[26] Ludwig T, Riethmuller C, Gekle M, et al.Nephrotoxicity of platinum complexes is related to basolateral organic cation transport[J].Kidney Int, 2004, 66(1):196-202.
[27] Okuda M, Tsuda K, Masaki K, et al.Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells:role of basolateral membrane transport[J].Toxicol Lett, 1999, 106(23):229-235.
[28] Urakami Y, OkudaM, Masuda S, et al.Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs[J].J Pharmacol Exp Ther, 1998, 287(2):800-805.
[29] Yonezawa A, Masuda S, Nishihara K, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2)in the rat[J].Biochem Pharmacol, 2005, 70(12):1823-1831.
[30] Filipski KK, Loops WJ, Verweij J, et al.Interaction of cisplatin with human organic cation transporter OCT2[J]. Clin Cancer res, 2008, 14(12):3875-3880.
[31] Hung DY, Chang P, Cheung K, et al.Cationic drug pharmacokinetics indiseased livers determined by fibrosis index, hepatic J.protein content, microsomal activity, and nature of drug[J].Pharmacol Exp Ther, 2002, 301(3): 1079-1087.
[32] Grundemann D, Hahne C, Berkels R, et al.Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT)and organic cation transporter 2 (OCT2)[J].J Pharmacol Exp Ther, 2003, 304(2):810-817.
[33] Somogyi A, Stockley C, Keal J, et al.Reduction of metformin renal tubular secretion by cimetidine in man[J].Br J Clin Pharmacol, 1987, 23(5):545-551.
[34] Choi MK, Jin QR, Jin HE, et al.Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin[J]. Biopharm Drug Dispos, 2007, 28(9):501-510.
[35] Wang Z, Yin O, Chow M, et al.OCT2 polymorphism in vivo renal functional consequence:Studies with metformin and cimetidine[J].Clin Pharmacol Ther, 2007, 18(7):637-645.